Ipsen : Deal avec Sutro Biopharma
>Deal sur un projet, en Oncologie, en fin de phase pré-clinique - Ipsen a signé hier avec Sutro Biopharma, un accord exclusif de licence mondiale pour un conjugué anticorps-petite molécule ciblant les tumeurs solides.Ipsen obtient les droits mondiaux exclusifs de développement et de commercialisation de STRO-003, un conjugué anticorps-petite molécule en voie de franchir les dernières étapes de développement préclinique. STRO-003 cible l’antigène tumoral ROR1, con...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.